Pfizer has authorized the development of a new Drug for AKL-1 Target Tumor Antibodies.

(Health Times reporter Wei Wei)
, Pfizer and Suzhou Development Pharmaceutical Co., Ltd. signed an agreement, Pfizer will grant Pioneering Pharmaceuticals the exclusive worldwide development, production and commercialization of a new anti-tumor antibody drug. The drug is expected to become the world's first human-source monoclonal antibody therapeutic drug targeting ALK-1.
ALK-1," or activator receptor-like kinase-1, mainly expressed in vascular endothelial cells, and is associated with the growth and migration of endothelial cells. By blocking the receptor, it can produce an inhibition of tumor vascular growth, reduce the blood flow and vascular formation of tumor blood vessels, and thus effectively slow down the tumor process. ALK-1 has a special target, its influence in tumor biology is extensive, not only inhibits vascular formation, but also causes changes in the tumor microenvironment. According to the concept of modern anti-tumor combination therapy, joint targeted therapy is also one of the key development directions in the future. AlK-1 antibody drugs, if successfully developed, can be combined with other target drugs to fight tumors, especially for liver cancer combined treatment, is expected to improve the prognosis of liver cancer patients.
developed by Pfizer in the early stages and completed two clinical Phase I trials in the United States, Italy, South Korea and Japan in 2014 and were validated in nearly 100 patients with advanced solid tumors. The drug is safe and some patients have achieved objective remission. Liver cancer patients in the dose-expanding group were given a certain rate of disease control. The above preliminary trial results are in urgent need of validation of Phase II clinical trials.
agreement, Pfizer will grant the rights of the ALK-1 program to the global ization of research and development, production and commercialization to pioneer pharmaceutical companies and provide support for completed preclinical, Phase I clinical studies and know-how. At the same time, Pfizer has retained options at different stages of its development to gain the right to develop, produce and commercialize outside China. Based on the results of Phase I clinical studies, Pioneer will conduct a global multi-center Phase II clinical trial and joint use of different drugs, and initiate work on the transfer of drug production to the country. At the same time, the development will also actively expand and explore the drug in addition to liver cancer in other types of cancer applications, with a view to the early benefit of the vast number of patients.
" the ALK-1 project is a major milestone in Pfizer's localization research and development strategy. "Pfizer has responded positively to The Health China 2030 Plan, working to develop more innovative drugs with local companies for the health and well-being of people in China and around the world," said Mr. Wu Wei, Head of Innovative Medicine sourcing at Pfizer. The development of new drugs for liver cancer, a high incidence of liver cancer in China, to bring clinical innovation and effective treatment options for the vast number of liver cancer patients in China, is a common goal of Pfizer and pioneering. "Since its inception in 2009, Pioneer Pharmaceuticals has focused on innovative drug research in the field of oncology," said Dr. Tong Youzhi, founder and president of
Pioneering Pharmaceuticals. There are currently several cancer projects under study that are progressing well. As we all know, the development of new drugs is a long process, often takes more than ten years, and the risk is very large. However, we are optimistic about the future clinical development and application of this Pfizer-mandated ALK-1 antibody drug, and we will strive to advance the future clinical development of the project, and strive to bring more timely and effective cancer treatment options to patients as soon as possible.
.